The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?

Overview[ - collapse ][ - ]

Purpose The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.
ConditionMajor Depressive Disorder
InterventionDrug: memantine
Drug: Placebo
PhaseN/A
SponsorUniversity of Iowa
Responsible PartyUniversity of Iowa
ClinicalTrials.gov IdentifierNCT00988663
First ReceivedOctober 1, 2009
Last UpdatedOctober 1, 2009
Last verifiedOctober 2009

Tracking Information[ + expand ][ + ]

First Received DateOctober 1, 2009
Last Updated DateOctober 1, 2009
Start DateNovember 2009
Estimated Primary Completion DateMay 2012
Current Primary Outcome MeasuresAssessment of whether Memantine protects memory and cognitive impairment caused by ECT. [Time Frame: 6 to 8 weeks] [Designated as safety issue: Yes]
Current Secondary Outcome MeasuresWhether memantine will improve response of Depression to Electroconvulsive therapy. [Time Frame: 6-8 weeks] [Designated as safety issue: No]

Descriptive Information[ + expand ][ + ]

Brief TitleThe Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?
Official TitleMemantine Augmentation of Electroconvulsive Therapy in Patients With Major Depression
Brief Summary
The purpose of this study is to determine whether memantine will enhance the therapeutic of
effect on depression and prevent memory and other cognitive problems caused by ECT.
Detailed Description
Patients will be assigned randomly either to a treatment group or a placebo groups. All
patients in both groups will be receiving standard ECT. The treatment group will receive
memantine. All patients will be given a battery of cognitive tests and test of depression
before ECT treatments start, after the 6th ECT treatment and after the completions of ECT.
An analysis will be performed to see if memantine causes any impact on the response to ECT
and prevents memory and cognitive impairment.
Study TypeInterventional
Study PhaseN/A
Study DesignAllocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
ConditionMajor Depressive Disorder
InterventionDrug: memantine
patient will receive 5mg daily for 7day then 10 mgm daily
Other Names:
NamendaDrug: Placebo
will give placebo that looks like memantine
Study Arm (s)
  • Active Comparator: Memantine arm
    Patient receiving ECT and Memantine
  • Placebo Comparator: placebo
    25 patients receiving ECT will will receive placebo

Recruitment Information[ + expand ][ + ]

Recruitment StatusNot yet recruiting
Estimated Enrollment50
Estimated Completion DateMay 2012
Estimated Primary Completion DateNovember 2011
Eligibility Criteria
Inclusion Criteria:

- Meets criteria for Major Depressive disorder

Exclusion Criteria:

- Neurological disease

- Mental retardation

- Seizure disorder
GenderBoth
Ages18 Years
Accepts Healthy VolunteersAccepts Healthy Volunteers
ContactsContact: Jerry L. Lewis, MD
319-384 5630
jerry-lewis@uiowa.edu
Location CountriesUnited States

Administrative Information[ + expand ][ + ]

NCT Number NCT00988663
Other Study ID NumbersMemantine ECT trial
Has Data Monitoring CommitteeYes
Information Provided ByUniversity of Iowa
Study SponsorUniversity of Iowa
CollaboratorsNot Provided
Investigators Principal Investigator: Jerry L Lewis, MD University of Iowa Hospitals and Clinic
Verification DateOctober 2009

Locations[ + expand ][ + ]

University of Iowa hosptitals and clinic
Iowa City, Iowa, United States, 50208
Contact: Jerry L Lewis, MD | 319-384-5630 | jerry-lewis@uiowa.edu
Principal Investigator: Jerry L Lewus, MD
Not yet recruiting